Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods: 2014-2024

Historic Finished Goods for Ocular Therapeutix (OCUL) over the last 11 years, with Dec 2024 value amounting to $1.3 million.

  • Ocular Therapeutix's Finished Goods rose 134.86% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 134.86%. This contributed to the annual value of $1.3 million for FY2024, which is 34.91% up from last year.
  • Per Ocular Therapeutix's latest filing, its Finished Goods stood at $1.3 million for FY2024, which was up 34.91% from $991,000 recorded in FY2023.
  • Ocular Therapeutix's 5-year Finished Goods high stood at $1.3 million for FY2024, and its period low was $257,000 during FY2021.
  • Moreover, its 3-year median value for Finished Goods was $991,000 (2023), whereas its average is $1.0 million.
  • In the last 5 years, Ocular Therapeutix's Finished Goods crashed by 56.07% in 2021 and then surged by 198.05% in 2022.
  • Ocular Therapeutix's Finished Goods (Yearly) stood at $585,000 in 2020, then crashed by 56.07% to $257,000 in 2021, then spiked by 198.05% to $766,000 in 2022, then grew by 29.37% to $991,000 in 2023, then spiked by 34.91% to $1.3 million in 2024.